This report is only as good as the data it is able to present. Higher response rates provide a fuller data set and allow the RSC to proceed in making the necessary improvements for inclusion in the ...

* In July 2021, Innovent and Ascentage Pharma (6855.HK) reached the agreement regarding the joint development and commercialization of olverembatinib in China. Dr. Kaijie He, Vice President of ...